Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for HCW Biologics Inc. (HCWB : NSDQ)

• Company Description    HCW Biologics Inc. is a preclinical stage biopharmaceutical company. It focused on discovering and developing novel immunotherapies. HCW Biologics Inc. is based in MIRAMAR, Fla. Number of Employees: 36

• Price / Volume Information    Yesterday's Closing Price: $3.32 Daily Weekly Monthly 20 Day Moving Average: 4,750,335 shares Shares Outstanding: 2.15 (millions) Market Capitalization: $7.14 (millions) Beta: 0.70 52 Week High: $62.40 52 Week Low: $2.77 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -23.50% -24.88% 12 Week -31.69% -37.98% Year To Date -81.39% -83.39%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 2929 N COMMERCE PKWY - MIRAMAR,FL 33025 USA ph: 954-842-2024 fax: 954-842-2037 mmcenroe@tiberend.com http://www.hcwbiologics.com

• General Corporate Information    Officers Hing C. Wong - Founder; Chief Executive Officer Scott T. Garrett - Chairperson of the Board of Directors Rebecca Byam - Chief Financial Officer Lisa M. Giles - Director Rick S. Greene - Director Peer Information HCW Biologics Inc. (CORR.) HCW Biologics Inc. (RSPI) HCW Biologics Inc. (CGXP) HCW Biologics Inc. (BGEN) HCW Biologics Inc. (GTBP) HCW Biologics Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 40423R204 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/13/25 Share - Related Items Shares Outstanding: 2.15 Most Recent Split Date: 4.00 (0.03:1) Beta: 0.70 Market Capitalization: $7.14 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/13/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: 8.58 EPS Growth vs. Year Ago Period: 57.56% vs. Previous Quarter: -13,480.00% Sales Growth vs. Year Ago Period: -98.87% vs. Previous Quarter: 40.00% ROE 06/30/25 - - 03/31/25 - - 12/31/24 - - ROA 06/30/25 - -40.72 03/31/25 - -90.09 12/31/24 - -105.31 Current Ratio 06/30/25 - 0.11 03/31/25 - 0.07 12/31/24 - 0.19 Quick Ratio 06/30/25 - 0.11 03/31/25 - 0.07 12/31/24 - 0.19 Operating Margin 06/30/25 - -1,368.55 03/31/25 - -1,712.94 12/31/24 - -1,169.57 Net Margin 06/30/25 - -1,368.55 03/31/25 - -1,712.94 12/31/24 - -1,169.57 Pre-Tax Margin 06/30/25 - -1,368.67 03/31/25 - -1,713.01 12/31/24 - -1,169.61 Book Value 06/30/25 - -0.02 03/31/25 - -7.62 12/31/24 - -6.08 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Capital 06/30/25 - - 03/31/25 - - 12/31/24 - -

Powered by Zacks Investment Research ©